Bailey B, Nguyen W, Cowman A, Sleebs B
Med Res Rev. 2023; 43(6):2303-2351.
PMID: 37232495
PMC: 10947479.
DOI: 10.1002/med.21975.
Valenciano A, Gomez-Lorenzo M, Vega-Rodriguez J, Adams J, Roth A
Trends Parasitol. 2022; 38(9):758-774.
PMID: 35780012
PMC: 9378454.
DOI: 10.1016/j.pt.2022.05.014.
Pewkliang Y, Rungin S, Lerdpanyangam K, Duangmanee A, Kanjanasirirat P, Suthivanich P
Malar J. 2018; 17(1):50.
PMID: 29370800
PMC: 5785895.
DOI: 10.1186/s12936-018-2198-4.
Gural N, Mancio-Silva L, He J, Bhatia S
Cell Mol Gastroenterol Hepatol. 2018; 5(2):131-144.
PMID: 29322086
PMC: 5756057.
DOI: 10.1016/j.jcmgh.2017.11.005.
March S, Ramanan V, Trehan K, Ng S, Galstian A, Gural N
Nat Protoc. 2015; 10(12):2027-53.
PMID: 26584444
PMC: 5867906.
DOI: 10.1038/nprot.2015.128.
Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.
Campo B, Vandal O, Wesche D, Burrows J
Pathog Glob Health. 2015; 109(3):107-22.
PMID: 25891812
PMC: 4455353.
DOI: 10.1179/2047773215Y.0000000013.
Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures.
Dembele L, Franetich J, Lorthiois A, Gego A, Zeeman A, Kocken C
Nat Med. 2014; 20(3):307-12.
PMID: 24509527
DOI: 10.1038/nm.3461.
Amazonian plant natural products: perspectives for discovery of new antimalarial drug leads.
Pohlit A, Lima R, Frausin G, Rocha E Silva L, Lopes S, Moraes C
Molecules. 2013; 18(8):9219-40.
PMID: 23917112
PMC: 6270278.
DOI: 10.3390/molecules18089219.
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax.
March S, Ng S, Velmurugan S, Galstian A, Shan J, Logan D
Cell Host Microbe. 2013; 14(1):104-15.
PMID: 23870318
PMC: 3780791.
DOI: 10.1016/j.chom.2013.06.005.
The painstaking discovery of the hidden face of the human plasmodia.
Pays J
Parasitol Res. 2012; 111(3):1301-7.
PMID: 22610446
DOI: 10.1007/s00436-012-2965-z.
Individual Plasmodium vivax msp1 variants within polyclonal P. vivax infections display different propensities for relapse.
Lin J, Juliano J, Kharabora O, Sem R, Lin F, Muth S
J Clin Microbiol. 2011; 50(4):1449-51.
PMID: 22205791
PMC: 3318509.
DOI: 10.1128/JCM.06212-11.
Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery.
Dembele L, Gego A, Zeeman A, Franetich J, Silvie O, Rametti A
PLoS One. 2011; 6(3):e18162.
PMID: 21483865
PMC: 3069045.
DOI: 10.1371/journal.pone.0018162.
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria.
Chattopadhyay R, Velmurugan S, Chakiath C, Andrews Donkor L, Milhous W, Barnwell J
PLoS One. 2010; 5(12):e14275.
PMID: 21151554
PMC: 3000326.
DOI: 10.1371/journal.pone.0014275.
Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S
Malar J. 2010; 9:308.
PMID: 21040545
PMC: 2988041.
DOI: 10.1186/1475-2875-9-308.
The hypnozoite concept, with particular reference to malaria.
Markus M
Parasitol Res. 2010; 108(1):247-52.
PMID: 20924610
DOI: 10.1007/s00436-010-2072-y.
A pre-emptive strike against malaria's stealthy hepatic forms.
Mazier D, Renia L, Snounou G
Nat Rev Drug Discov. 2009; 8(11):854-64.
PMID: 19876040
DOI: 10.1038/nrd2960.
The hypnozoite and relapse in primate malaria.
Cogswell F
Clin Microbiol Rev. 1992; 5(1):26-35.
PMID: 1735093
PMC: 358221.
DOI: 10.1128/CMR.5.1.26.
